Gruppo Oncologico Italia Meridionale
Quick facts
Phase 3 pipeline
- carboplatin paclitaxel bevacizumab · Oncology
This combination uses carboplatin and paclitaxel as chemotherapy agents to damage cancer cell DNA and disrupt microtubules, while bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Gruppo Oncologico Italia Meridionale portfolio CI brief
- Gruppo Oncologico Italia Meridionale pipeline updates RSS
Frequently asked questions about Gruppo Oncologico Italia Meridionale
What is Gruppo Oncologico Italia Meridionale's pipeline?
Gruppo Oncologico Italia Meridionale has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include carboplatin paclitaxel bevacizumab.
Related
- Sector hub: All tracked pharma companies